KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cme (CME) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cme (CME) over the last 17 years, with Q3 2025 value amounting to 64.97%.

  • Cme's EBITDA Margin fell 14500.0% to 64.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 66.25%, marking a year-over-year increase of 11500.0%. This contributed to the annual value of 64.13% for FY2024, which is 25500.0% up from last year.
  • According to the latest figures from Q3 2025, Cme's EBITDA Margin is 64.97%, which was down 14500.0% from 68.36% recorded in Q2 2025.
  • Cme's 5-year EBITDA Margin high stood at 69.13% for Q1 2025, and its period low was 55.06% during Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 63.63% (2023), whereas its average is 63.19%.
  • The largest annual percentage gain for Cme's EBITDA Margin in the last 5 years was 81800bps (2021), contrasted with its biggest fall of -45300bps (2021).
  • Over the past 5 years, Cme's EBITDA Margin (Quarter) stood at 55.06% in 2021, then grew by 0bps to 55.33% in 2022, then rose by 8bps to 59.97% in 2023, then grew by 4bps to 62.09% in 2024, then rose by 5bps to 64.97% in 2025.
  • Its last three reported values are 64.97% in Q3 2025, 68.36% for Q2 2025, and 69.13% during Q1 2025.